Abstract

Novel Technologies For the Detection of Clinically Relevant DNA Alterations in Circulating DNA

Mike Makrigiorgos, Professor, Dana Farber Cancer Institute and Harvard Medical School

With the increasing interest in treatment assessment using circulating DNA, sensitive and multiplexed detection of tumor-derived alterations in blood are desirable. We provide novel mutation enrichment-based methods that (a) enable several orders of magnitude improvement of microsatellite instability or mutations than currently possible; (b) are highly multiplex-able; (c) reduce the cost of both sample preparation and re-sequencing.  Application in circulating DNA from clinical cancer samples will be presented.